Literature DB >> 25056851

Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy.

Anna Weiss1, Katherine C Lee, Yajahira Romero, Erin Ward, Yeunjeong Kim, Haydee Ojeda-Fournier, John Einck, Sarah L Blair.   

Abstract

INTRODUCTION: Calcifications can be indicative of malignancy, but calcifications also can be a byproduct of necrotic tissue as cancer cells die. Current treatment regimens require excision of calcifications. The objective of this study was to examine the correlation between the extent of calcification on mammography and actual tumor size after neoadjuvant chemotherapy (NAC) as well as magnetic resonance imaging (MRI) for comparison.
METHODS: We retrospectively reviewed all patients at the University of California, San Diego, who underwent NAC for breast cancer between 2007 and 2013. Pearson correlation coefficients were computed between breast imaging and pathological measurements.
RESULTS: There were 136 patients total. Average age was 51 years. Fifty-three patients had calcifications on imaging (calc+); 83 did not (calc-). In the calc- group, extent of disease measured by mammogram (MMG) and MRI correlated moderately well with pathological tumor size (0.46 and 0.48, p = not significant). In the calc+ group, MRI was more likely to correlate with pathology than MMG (0.55 vs. -0.12, p = 0.01). Twenty-five calc+ patients had increased calcification after NAC; six of these had complete pathologic response. MRI correlated better with tumor size on pathology in patients with anti-HER2neu-based regimens than in patients with cytotoxic chemotherapy-alone regimens (0.88 vs. 0.4, p = 0.0001). MRI also is more accurate at predicting pathological tumor size in patients with triple negative disease (p = 0.002).
CONCLUSIONS: Magnetic resonance imaging correlated well while MMG calcification measurements correlated poorly with tumor size on final pathology. Extent of calcifications on diagnostic mammography may not be accurate in preoperative evaluation of breast cancers after NAC.

Entities:  

Mesh:

Year:  2014        PMID: 25056851     DOI: 10.1245/s10434-014-3914-0

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  13 in total

Review 1.  Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy.

Authors:  Tari A King; Monica Morrow
Journal:  Nat Rev Clin Oncol       Date:  2015-04-07       Impact factor: 66.675

Review 2.  Trends and controversies in multidisciplinary care of the patient with breast cancer.

Authors:  Laura S Dominici; Monica Morrow; Elizabeth Mittendorf; Jennifer Bellon; Tari A King
Journal:  Curr Probl Surg       Date:  2016-11-29       Impact factor: 1.909

Review 3.  Locoregional Management After Neoadjuvant Chemotherapy.

Authors:  Monica Morrow; Atif J Khan
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

4.  Do Calcifications Seen on Mammography After Neoadjuvant Chemotherapy for Breast Cancer Always Need to Be Excised?

Authors:  Yara Feliciano; Anita Mamtani; Monica Morrow; Michelle M Stempel; Sujata Patil; Maxine S Jochelson
Journal:  Ann Surg Oncol       Date:  2017-01-05       Impact factor: 5.344

5.  Do MRI and mammography reliably identify candidates for breast conservation after neoadjuvant chemotherapy?

Authors:  Maxine S Jochelson; Katharine Lampen-Sachar; Girard Gibbons; Chau Dang; Diana Lake; Elizabeth A Morris; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2015-03-17       Impact factor: 5.344

6.  Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?

Authors:  Bruna M Thompson; Luciano F Chala; Carlos Shimizu; Max S Mano; José R Filassi; Felipe C Geyer; Ulysses S Torres; Giselle Guedes Netto de Mello; Cláudia da Costa Leite
Journal:  Eur Radiol       Date:  2021-10-30       Impact factor: 7.034

7.  Microcalcification of Tumor is a Predictor of Response to Neoadjuvant Chemotherapy for Invasive Breast Carcinoma.

Authors:  Aya Murata; Naoko Sannomiya; Naoki Miyamoto; Naoyuki Ueda; Akira Kamida; Yuki Koyanagi; Haruki Nagira; Eriko Matsuda; Yuki Hashimoto; Kengo Sato; Yumi Hirooka; Keiko Hosoya; Yuzo Takagi; Yuko Tanaka; Kunio Araki; Kiyosuke Ishiguro; Yasuaki Hirooka
Journal:  Yonago Acta Med       Date:  2015-08-18       Impact factor: 1.641

8.  Magnetic Resonance Imaging after Completion of Neoadjuvant Chemotherapy Can Accurately Discriminate between No Residual Carcinoma and Residual Ductal Carcinoma In Situ in Patients with Triple-Negative Breast Cancer.

Authors:  Seho Park; Jung Hyun Yoon; Joohyuk Sohn; Hyung Seok Park; Hee Jung Moon; Min Jung Kim; Eun-Kyung Kim; Seung Il Kim; Byeong-Woo Park
Journal:  PLoS One       Date:  2016-02-11       Impact factor: 3.240

9.  Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor.

Authors:  Yeong Yi An; Sung Hun Kim; Bong Joo Kang
Journal:  World J Surg Oncol       Date:  2017-11-06       Impact factor: 2.754

Review 10.  Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.

Authors:  Ella F Jones; Deep K Hathi; Rita Freimanis; Rita A Mukhtar; A Jo Chien; Laura J Esserman; Laura J Van't Veer; Bonnie N Joe; Nola M Hylton
Journal:  Cancers (Basel)       Date:  2020-06-09       Impact factor: 6.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.